Adilia Hormigo, MD, PhD
- PROFESSOR | Neurology
- PROFESSOR | Neurosurgery
- PROFESSOR | Medicine
Specialty:
NeurologyResearch Topics:
Angiogenesis, Anti-Tumor Therapy, Brain, Cancer, Immunology, Metastasis, Stem Cells, Tumorigenesis
Adilia Hormigo, MD, PhD is Director of the Neuro-Oncology Program for The Mount SinaiHospital and the Mount Sinai Health System, and Professor in the Department of Neurology, Medicine (Division of Hematology-Oncology), and Neurosurgery. She is a neuro-oncologist specializing in the care of patients with primary brain tumors, CNS metastases, and the neurological complications of cancer and its treatment. She employs a multidisciplinary team approach to ensure that patients receive compassionate, comprehensive care.
Dr. Hormigo obtained her MD with honors from the University of Lisbon Medical School in Portugal, and her PhD from New York University. She completed residencies in Neurology at the University Hospital of Lisbon Medical School, Portuguese Oncological Institute and New York Presbyterian-Weill Medical College of Cornell University and Memorial Sloan-Kettering Cancer Center. She completed both research and clinical neuro-oncology fellowships under Jerome B. Posner. She served as faculty at Memorial Sloan-Kettering Cancer Center and Cornell University. She trained a number of fellows, many of whom are faculty in leading programs of neuro-oncology in the country and abroad.
Her clinical and translational research focuses on new strategies including personalized treatment for patients with brain tumors with emphasis on immunotherapy, developing new biomarkers and studying the microenvironment of brain tumors. Her goal is to achieve the highest level of patient care and clinical excellence. She sees patients at the Ruttenberg Treatment Center of the Tisch Cancer Institute.
Certifications
Neurology, American Board of Psychiatry and Neurology
Clinical Focus
- Brain Metastasis
- Brain Tumors
- Lumbar Puncture
- Paraneoplastic Syndromes, Central Nervous System
- Primary Central Nervous System Lymphoma
- Spinal Cord Tumors
Education
MD, Faculdade de Medicina Lisboa
Research Fellow, Memorial Sloan-Kettering Cancer Center
PhD, New York University
Internship, Neurology, Universidade De Lisboa
Residency, Neurology, Universidade De Lisboa
Internship, Internal Medicine, New York Presbyterian - Weill Cornell Medical Center
Residency, Neurology, New York Presbyterian - Weill Cornell Medical Center
Fellowship, Neuro-Oncology, Memorial Sloan-Kettering Cancer Center
-
2013
Fellow -
2012
Advanced Techniques in Molecular Neuroscience -
2005
Excellence in Teaching Award for the Neurology Clerkship -
2003
Resident Award -
1990
Second UCB Neurology Award -
1989
Biofarma
Chen IE, Swinburne N, Tsankova NM, Hefti MM, Aggarwal A, Doshi AH, Hormigo A, Delman BN, Nael K. Sequential Apparent Diffusion Coefficient for Assessment of Tumor Progression in Patients with Low-Grade Glioma. AJNR. American Journal of Neuroradiology 2018 Jun; 39(6).
Nael K, Bauer AH, Hormigo A, Lemole M, Germano IM, Puig J, Stea B, Delman BN, Nael K. Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma. AJR. American Journal of Roentgenology 2018 Jan; 210(1).
Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N, Stea B. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer 2016 11; 16(1).
Majd N, Wei X, Demopoulos A, Hormigo A, Chari A. Characterization of central nervous system multiple myeloma in the era of novel therapies. Leukemia & lymphoma 2016 07; 57(7).
Rhome R, Fisher R, Hormigo A, Parikh RR, Chaudhry A, Blondin N. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. Journal of Neuro-oncology 2016 06; 128(2).
Majd N, Wei X, Demopoulos A, Hormigo A, Chari A. Characterization of central nervous system multiple myeloma in the era of novel therapies. Leukemia & Lymphoma 2016 07; 57(7).
Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 2016 Oct; 22(19).
Fisher R, Hormigo A, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Adjuvant therapy for patients with newly diagnosed glioblastoma. In: Glioblastoma Multiforme: Neurological Symptoms, Therapeutic Management, and Outcome. Hauppauge, NY, Nova Science Publishers;.
Iwamoto FM, Hormigo A, Hormigo A, Lemole M, Germano IM, Puig J, Stea B, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. Frontiers in Oncology 2014; 4.
Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clinical Cancer Research : an official journal of the American Association for Cancer Research 2014 Oct; 20(19).
Ding BS, James D, Iyer R, Falciatori I, Hambardzumyan D, Wang S, Butler JM, Rabbany SY, Hormigo A, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Prominin 1/CD133 endothelium sustains growth of proneural glioma. PloS One 2013; 8(4).
Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-oncology 2013 Feb; 15(2).
Pentsova E, Liu A, Rosenblum M, O'Reilly E, Chen X, Hormigo A, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. Journal of Neuro-oncology 2012 Jan; 106(1).
Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro-oncology 2011 Nov; 13(11).
Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. Journal of Neuro-oncology 2011 Dec; 105(3).
Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Holland EC, DeAngelis LM, Hormigo A. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Annals of Neurology 2011 Jul; 70(1).
Hormigo A, Ding BS, Rafii S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Holland EC, DeAngelis LM, Hormigo A. A target for antiangiogenic therapy: vascular endothelium derived from glioblastoma. Proceedings of the National Academy of Sciences of the United States of America 2011 Mar; 108(11).
Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE, DeAngelis LM, Hormigo A. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2009 Aug; 27(23).
Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE, DeAngelis LM, Hormigo A. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. Journal of Neuro-oncology 2008 Jul; 88(3).
Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE, Rosenblum M, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. Journal of Neuro-oncology 2007 Nov; 85(2).
Hormigo A, Gutin PH, Rafii S, Deangelis LM, Abrey LE, Rosenblum M, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell 2007 Jan; 11(1).
Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clinical Cancer Research : an official journal of the American Association for Cancer Research 2006 Oct; 12(19).
Deangelis LM, Hormigo A, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. Treatment of primary central nervous system lymphoma. Seminars in Oncology 2004 Oct; 31(5).
Hormigo A, Abrey L, Heinemann MH, DeAngelis LM, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. British Journal of Haematology 2004 Jul; 126(2).
Hormigo A, Liberato B, Lis E, DeAngelis LM, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. Nonconvulsive status epilepticus in patients with cancer: imaging abnormalities. Archives of Neurology 2004 Mar; 61(3).
Hormigo A, DeAngelis LM, Lis E, DeAngelis LM. Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clinical Lymphoma 2003 Jun; 4(1).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Hormigo did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.